Ingrid Choong
No más puestos en curso
Fortuna: 3 396 $ al 30/04/2024
Historial de carrera de Ingrid Choong
Antiguos cargos conocidos de Ingrid Choong.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
EIGER BIOPHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | - | 01/09/2023 |
Contacto de Relaciones con Inversores | 01/01/2008 | - | |
Public Communications Contact | 01/01/2008 | - | |
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Contacto de Relaciones con Inversores | - | 29/03/2016 |
Corporate Officer/Principal | 11/08/2011 | - | |
VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/1999 | 01/01/2008 |
Formación de Ingrid Choong.
California Institute of Technology | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Operativa
Investor Relations Contact | 2 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Ingrid Choong
- Experiencia